Insmed Incorporated · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-02$177.12 RISE2026-05-08$101.35 PEAK2026-05-13$117.99 131d | -42.8% 126d | Missed | Missed | — | — | +16.4% 5d | Missed |
DROP2025-12-01$211.41 RISE2026-03-20$136.00 PEAK2026-04-01$164.86 121d | -35.7% 109d | Missed | Missed | — | — | +21.2% 12d | Missed |
DROP2025-02-19$83.83 RISE2025-04-10$64.81 PEAK2025-06-24$105.90 125d | -22.7% 50d | Missed | Missed | — | — | +63.4% 75d | Missed |
DROP2024-08-22$79.01 RISE2024-11-15$66.29 PEAK2025-02-05$81.44 167d | -16.1% 85d | Missed | Missed | — | — | +22.9% 82d | Missed |
DROP2024-02-16$29.51 RISE2024-05-24$22.00 PEAK2024-07-16$77.98 151d | -25.4% 98d | Missed | Missed | — | — | +254.5% 53d | Missed |
DROP2023-12-28$31.74 RISE2024-04-22$24.11 PEAK2024-07-16$77.98 201d | -24.0% 116d | Missed | Missed | — | — | +223.4% 85d | Missed |
DROP2023-12-28$31.74 RISE2024-03-15$25.72 PEAK2024-06-11$61.87 166d | -19.0% 78d | Missed | Missed | — | — | +140.6% 88d | Missed |
DROP2023-02-02$21.73 RISE2023-03-22$16.26 PEAK2023-05-22$20.31 109d | -25.2% 48d | Missed | Missed | — | — | +24.9% 61d | Missed |
DROP2022-09-12$25.28 RISE2023-01-09$17.79 PEAK2023-02-02$21.73 143d | -29.6% 119d | Missed | Missed | — | — | +22.1% 24d | Missed |
DROP2022-08-10$28.21 RISE2022-10-27$16.98 PEAK2023-01-24$21.59 167d | -39.8% 78d | Missed | Missed | — | — | +27.1% 89d | Missed |
DROP2022-04-13$25.71 RISE2022-08-01$20.88 PEAK2022-08-10$28.21 119d | -18.8% 110d | Missed | Missed | — | — | +35.1% 9d | Missed |
DROP2022-04-13$25.71 RISE2022-06-16$17.32 PEAK2022-08-10$28.21 119d | -32.6% 64d | Missed | Missed | — | — | +62.9% 55d | Missed |
DROP2022-01-03$28.13 RISE2022-05-11$17.07 PEAK2022-08-08$27.95 217d | -39.3% 128d | Missed | Missed | — | — | +63.7% 89d | Missed |
DROP2021-11-04$33.45 RISE2022-03-14$21.20 PEAK2022-04-13$25.71 160d | -36.6% 130d | Missed | Missed | — | — | +21.3% 30d | Missed |
DROP2021-11-04$33.45 RISE2022-01-27$20.42 PEAK2022-04-13$25.71 160d | -39.0% 84d | Missed | Missed | — | — | +25.9% 76d | Missed |
1–15 / 21 1 / 2 | |||||||
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.
Insmed Incorporated (INSM) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 10:30 AM EDTCompany ParticipantsSara Bonstein - Chief...
With a 5-year average revenue growth rate of 23.8%, Insmed Incorporated (NASDAQ:INSM) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 13, Truist lowered the firm’s price target on Insmed Incorporated (NASDAQ:INSM) to $185 from $205 while maintaining a Buy rating on the shares. The analyst said the firm updated […]
With a 5-year average revenue growth rate of 23.8%, Insmed Incorporated (NASDAQ:INSM) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 13, Truist lowered the firm’s price target on Insmed Incorporated (NASDAQ:INSM) to $185 from $205 while maintaining a Buy rating on the shares. The analyst said the firm updated […]
Insmed Stock Snapshot After Recent Moves Insmed (INSM) has drawn fresh attention after recent trading left the share price at US$107.15, with performance mixed over different periods and longer term returns contrasting with weaker month and past 3 months moves. See our latest analysis for Insmed. Recent trading has seen momentum fade, with the share price down 25.84% over 30 days and 28.81% over 90 days. This comes even as the 1 year total shareholder return sits at 57.85% and the 3 year...
Insmed Stock Snapshot After Recent Moves Insmed (INSM) has drawn fresh attention after recent trading left the share price at US$107.15, with performance mixed over different periods and longer term returns contrasting with weaker month and past 3 months moves. See our latest analysis for Insmed. Recent trading has seen momentum fade, with the share price down 25.84% over 30 days and 28.81% over 90 days. This comes even as the 1 year total shareholder return sits at 57.85% and the 3 year...
Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended
Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended
Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide.
Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide.
Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide.
Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide.
Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings.
Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings.
Common StockDebt SecuritiesWe or any selling securityholder may from time to time offer to sell the securities identified above in amounts, at prices and on terms determined at the time of the offering and described in
Insmed Inc: Insmed Inc: files for mixed shelf offering; size not disclosed - SEC filing...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| INSM | -19.77% | -26.93% | -38.57% | +53.32% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -22.74% | -21.22% | -35.13% | +40.63% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 13.16M | $2.15B | 0.11% | Added+32.6% | 2026-03-31 |
| DEShaw | quant | 5.63M | $919.93M | 0.55% | Added+29.3% | 2026-03-31 |
| StateStreet | passive | 5.55M | $907.81M | 0.03% | Added+6.7% | 2026-03-31 |
| Wellington | fundamental | 399.0K | $65.25M | 0.01% | Trimmed-17.9% | 2026-03-31 |
| Bridgewater | macro | 295.6K | $48.33M | 0.22% | New | 2026-03-31 |
| TwoSigma | quant | 237.0K | $38.76M | 0.03% | Trimmed-75.4% | 2026-03-31 |
| RenTech | quant | 20.3K | $3.32M | 0.01% | Trimmed-21.6% | 2026-03-31 |
| TRowePrice | fundamental | 3.09M | $505.74K | 0.06% | Trimmed-23.4% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | Smith Michael Alexander | Chief Legal Officer | S Open-market sale | 6,149 | $108.47 | −$667.0K |
| 2026-05-20 | Lewis William | Chair and CEO | M Option exercise(deriv) | 4,440 | — | +$0 |
| 2026-05-20 | Lewis William | Chair and CEO | M Option exercise(deriv) | 6,259 | — | +$0 |
| 2026-05-20 | Lewis William | Chair and CEO | S Open-market sale | 7,975 | $106.97 | −$853.1K |
| 2026-05-20 | Lewis William | Chair and CEO | S Open-market sale | 11,836 | $106.39 | −$1.26M |
| 2026-05-20 | Lewis William | Chair and CEO | S Open-market sale | 5,753 | $105.32 | −$605.9K |
| 2026-05-20 | Lewis William | Chair and CEO | M Option exercise | 4,440 | $17.16 | +$76.2K |
| 2026-05-20 | Lewis William | Chair and CEO | M Option exercise | 6,259 | $30.46 | +$190.6K |
| 2026-05-15 | Lewis William | Chair and CEO | S Open-market sale | 13,283 | $116.18 | −$1.54M |
| 2026-05-15 | LEE LEO | Director | A Grant / award | 3,305 | — | — |
| 2026-05-15 | Desjardins Clarissa | Director | A Grant / award | 3,305 | — | — |
| 2026-05-15 | Brennan David R | Director | A Grant / award | 3,305 | — | — |
| 2026-05-15 | SHAROKY MELVIN MD | Director | A Grant / award | 3,305 | — | — |
| 2026-05-15 | Smith Michael Alexander | Chief Legal Officer | S Open-market sale | 4,109 | $116.18 | −$477.4K |
| 2026-05-15 | Flammer Martina M.D. | Chief Medical Officer | S Open-market sale | 10,479 | $117.54 | −$1.23M |
| 2026-05-15 | Flammer Martina M.D. | Chief Medical Officer | S Open-market sale | 3,384 | $116.18 | −$393.2K |
| 2026-05-15 | Flammer Martina M.D. | Chief Medical Officer | S Open-market sale | 4,470 | $112.76 | −$504.0K |
| 2026-05-15 | ANDERSON ELIZABETH M | Director | A Grant / award | 3,305 | — | — |
| 2026-05-15 | Adsett Roger | Chief Operating Officer | S Open-market sale | 5,837 | $116.18 | −$678.1K |
| 2026-05-15 | SCHAFER CAROL | Director | A Grant / award | 3,305 | — | — |
| 2026-05-15 | Bonstein Sara | Chief Financial Officer | S Open-market sale | 8,272 | $116.18 | −$961.0K |
| 2026-05-13 | Flammer Martina M.D. | Chief Medical Officer | M Option exercise(deriv) | 12,949 | — | +$0 |
| 2026-05-13 | Flammer Martina M.D. | Chief Medical Officer | S Open-market sale | 830 | $101.18 | −$84.0K |
| 2026-05-13 | Flammer Martina M.D. | Chief Medical Officer | S Open-market sale | 12,119 | $100.35 | −$1.22M |
| 2026-05-13 | Flammer Martina M.D. | Chief Medical Officer | M Option exercise | 12,949 | $17.07 | +$221.0K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.77 | — | — |
| 2026-05-07 | -1.00 | -0.76 | +23.93% |
| 2026-02-19 | -1.17 | -1.54 | -31.92% |
| 2025-10-30 | -1.37 | -1.75 | -27.80% |
| 2025-08-07 | -1.31 | -1.70 | -29.60% |
| 2025-05-08 | -1.36 | -1.42 | -4.22% |
| 2025-02-20 | -1.16 | -1.32 | -13.32% |
| 2024-10-31 | -1.21 | -1.27 | -4.89% |
| 2024-08-08 | -1.23 | -1.94 | -58.20% |
| 2024-05-09 | -1.20 | -1.06 | +11.47% |
| 2024-02-22 | -1.13 | -1.28 | -13.27% |
| 2023-10-26 | -1.11 | -1.11 | +0.22% |
| 2023-08-03 | -1.12 | -1.78 | -58.93% |
| 2023-05-04 | -1.10 | -1.17 | -6.36% |
| 2023-02-23 | -1.02 | -1.21 | -18.19% |
| 2022-10-27 | -0.87 | -1.09 | -24.88% |